Chinese expert consensus on Bruton tyrosine kinase inhibitors in the treatment of B-cell malignancies

Targeted therapy with Bruton tyrosine kinase (BTK) inhibitors have revolutionized the treatment of patients with various B-cell malignancies. BTK inhibitors such as ibrutinib, zanubrutinib, orelabrutinib, and acalabrutinib have shown good clinical efficacy and better safety profiles than those of tr...

Descripción completa

Detalles Bibliográficos
Autores principales: Song, Yuqin, Wu, Shang-Ju, Shen, Zhixiang, Zhao, Donglu, Chan, Thomas Sau Yan, Huang, Huiqiang, Qiu, Lugui, Li, Jianyong, Tan, Tran-der, Zhu, Jun, Song, Yongping, Huang, Wei-Han, Zhao, Weili, Liu, Herman Sung Yu, Xu, Wei, Chen, Naizhi, Ma, Jun, Chang, Cheng-Shyong, Tse, Eric Wai Choi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10578030/
https://www.ncbi.nlm.nih.gov/pubmed/37845755
http://dx.doi.org/10.1186/s40164-023-00448-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10578030/
https://www.ncbi.nlm.nih.gov/pubmed/37845755
http://dx.doi.org/10.1186/s40164-023-00448-5

Ejemplares similares